Erdem Akbal1, Erdem Koçak2, Ömer Akyürek3, Seyfettin Köklü4, Hikmetullah Batgi5, Mehmet Şenes6. 1. Department of Gastroenterology, Çanakkale Onsekiz Mart University, Çanakkale, Turkey. 2. Department of Gastroenterology, Çanakkale State Hospital, Çanakkale, Turkey. 3. Department of Internal Medicine, Mevlana University Faculty of Medicine, Konya, Turkey. dromerakyurek@gmail.com. 4. Department of Gastroenterology, School of Medicine Hacettepe University, Ankara, Turkey. 5. Department of Internal Medicine, Ankara Education and Research Hospital, Ankara, Turkey. 6. Department of Medical Biochemistry, Ankara Education and Research Hospital, Ankara, Turkey.
Abstract
BACKGROUND AND AIMS: Liver fatty acid-binding protein (L-FABP) is a small cytoplasmic protein. The aim of the current study was to investigate L-FABP levels and to determine their diagnostic value for non-alcoholic fatty liver disease (NAFLD). METHODS: We enrolled in this study 24 consecutive patients with NAFLD who were diagnosed with elevated transaminases and with steatosis by ultrasonograph. The control group consisted of 22 healthy control subjects matched for age and gender. Serum levels of L-FABP were determined by enzyme-linked immunosorbent assay. RESULTS: L-FABP levels in NAFLD patients were higher than in the control group (levels were 41,976 ± 18,998 and 17048 ± 5021 pg/mL, respectively). A strong correlation was found between serum L-FABP concentrations and aspartate aminotransferase, alanine aminotransferase, body mass index, glucose and γ-glutamyltransferase levels. A level of 284,000 pg/mL L-FABP had 73% sensitivity and 100% specificity. Positive and negative predictive values for L-FABP were 100 and 79%, respectively. CONCLUSIONS: Serum L-FABP can be considered as a new diagnostic marker for detecting non-alcoholic fatty liver disease.
BACKGROUND AND AIMS: Liver fatty acid-binding protein (L-FABP) is a small cytoplasmic protein. The aim of the current study was to investigate L-FABP levels and to determine their diagnostic value for non-alcoholic fatty liver disease (NAFLD). METHODS: We enrolled in this study 24 consecutive patients with NAFLD who were diagnosed with elevated transaminases and with steatosis by ultrasonograph. The control group consisted of 22 healthy control subjects matched for age and gender. Serum levels of L-FABP were determined by enzyme-linked immunosorbent assay. RESULTS:L-FABP levels in NAFLD patients were higher than in the control group (levels were 41,976 ± 18,998 and 17048 ± 5021 pg/mL, respectively). A strong correlation was found between serum L-FABP concentrations and aspartate aminotransferase, alanine aminotransferase, body mass index, glucose and γ-glutamyltransferase levels. A level of 284,000 pg/mL L-FABP had 73% sensitivity and 100% specificity. Positive and negative predictive values for L-FABP were 100 and 79%, respectively. CONCLUSIONS: Serum L-FABP can be considered as a new diagnostic marker for detecting non-alcoholic fatty liver disease.
Authors: Maurice M A L Pelsers; Alireza Morovat; Graeme J M Alexander; Wim T Hermens; Andrew K Trull; Jan F C Glatz Journal: Clin Chem Date: 2002-11 Impact factor: 8.327
Authors: F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi Journal: J Clin Endocrinol Metab Date: 2004-12-14 Impact factor: 5.958
Authors: Carla Guzmán; Marta Benet; Sandra Pisonero-Vaquero; Marta Moya; M Victoria García-Mediavilla; M Luz Martínez-Chantar; Javier González-Gallego; José Vicente Castell; Sonia Sánchez-Campos; Ramiro Jover Journal: Biochim Biophys Acta Date: 2013-01-12
Authors: Maartje A J van den Broek; Johanne G Bloemen; Simon A W G Dello; Marcel C G van de Poll; Steven W M Olde Damink; Cornelis H C Dejong Journal: J Hepatol Date: 2010-12-13 Impact factor: 25.083
Authors: Hossein Sendi; Ivy Mead; Meimei Wan; Marjan Mehrab-Mohseni; Kenneth Koch; Anthony Atala; Herbert L Bonkovsky; Colin E Bishop Journal: PLoS One Date: 2018-07-19 Impact factor: 3.240